Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890663189> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W2890663189 endingPage "9002" @default.
- W2890663189 startingPage "9002" @default.
- W2890663189 abstract "9002 Background: Atezo (anti–PD-L1) inhibits PD-L1 to restore anticancer immunity; bev may enhance atezo efficacy by inhibiting VEGF immunosuppression and promoting T-cell tumor infiltration. IMpower150 is the first randomized Ph 3 trial evaluating atezo + chemo (carboplatin [C] + paclitaxel [P]) ± bev vs CP + bev in 1L NSQ NSCLC. PFS benefit was observed with atezo + CP + bev vs CP + bev regardless of PD-L1 expression. Here we present the IMpower150 interim OS results. Methods: 1202 patients (pts) received atezo 1200 mg + C AUC 6 + P 200 mg/m2 (Arm A) or atezo + CP + bev 15 mg/kg (Arm B) vs CP + bev (Arm C) IV q3w for 4 or 6 cycles per investigator (INV); then maintenance atezo, atezo + bev, or bev, respectively. Co-primary endpoints were INV-assessed PFS in the ITT-WT (EGFR/ALK WT) and in WT pts with expression of a tumor T-effector gene signature (Teff-high WT) and OS in the ITT-WT. Data cutoff: 1/22/2018. Results: 349, 359, and 337 ITT-WT pts were enrolled in Arms A, B, and C, respectively, with median age 63 y, 62% male, 85% current/previous smokers, and 42% ECOG PS 0. With 13.5 mo min FU, OS was improved in Arm B vs C (HR, 0.78 [95% CI: 0.64, 0.96]; P = 0.016) in the ITT-WT; populations of interest are shown in the Table. Arm A vs C OS HR was 0.88 (95% CI: 0.72, 1.08; P = 0.204). In all treated patients, Gr 3-4 treatment-related AEs occurred in 43%, 57%, and 49% of pts in Arms A, B, and C, respectively. Conclusions: IMpower150 showed a significant OS benefit with atezo + CP + bev vs CP + bev in 1L NSQ NSCLC, and no new safety signals were seen. Clinical trial information: NCT02366143. IC, tumor-infiltrating immune cells; NE, not estimable; TC, tumor cells. a WT excludes pts with EGFR or ALK genomic alterations. b Present at baseline. TC1/2/3 or IC1/2/3 = PD-L1+ ≥ 1% of TC or IC; TC0 and IC0 = PD-L1+ < 1% of TC and IC Arm B vs C OS in populations of interest. Population No. of Pts HR (95% CI) mOS, mo Arm B Arm C ITT-WTa 696 0.78 (0.64, 0.96) 19.2 14.7 ITT 800 0.76 (0.63, 0.93) 19.8 14.9 EGFR/ALK+ 104 0.54 (0.29, 1.03) NE 17.5 Liver metastasesb 94 0.54 (0.33, 0.88) 13.2 9.1 Subgroups in ITT-WT TC1/2/3 or IC1/2/3 357 0.77 (0.58, 1.04) 22.5 16.4 TC0 and IC0 339 0.82 (0.62, 1.08) 17.1 14.1 Teff-high 285 0.83 (0.59, 1.17) 25.0 16.7 Teff-low 377 0.78 (0.60, 1.02) 17.6 14.3" @default.
- W2890663189 created "2018-09-27" @default.
- W2890663189 creator A5001204975 @default.
- W2890663189 creator A5001928949 @default.
- W2890663189 creator A5002934898 @default.
- W2890663189 creator A5004037726 @default.
- W2890663189 creator A5030455508 @default.
- W2890663189 creator A5041853768 @default.
- W2890663189 creator A5042110139 @default.
- W2890663189 creator A5043421969 @default.
- W2890663189 creator A5044171245 @default.
- W2890663189 creator A5049504224 @default.
- W2890663189 creator A5055964030 @default.
- W2890663189 creator A5060572768 @default.
- W2890663189 creator A5067155382 @default.
- W2890663189 creator A5071263994 @default.
- W2890663189 creator A5071722627 @default.
- W2890663189 creator A5072962574 @default.
- W2890663189 creator A5078629724 @default.
- W2890663189 creator A5087836238 @default.
- W2890663189 creator A5091816731 @default.
- W2890663189 date "2018-05-20" @default.
- W2890663189 modified "2023-09-30" @default.
- W2890663189 title "Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC." @default.
- W2890663189 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.9002" @default.
- W2890663189 hasPublicationYear "2018" @default.
- W2890663189 type Work @default.
- W2890663189 sameAs 2890663189 @default.
- W2890663189 citedByCount "65" @default.
- W2890663189 countsByYear W28906631892018 @default.
- W2890663189 countsByYear W28906631892019 @default.
- W2890663189 countsByYear W28906631892020 @default.
- W2890663189 countsByYear W28906631892021 @default.
- W2890663189 countsByYear W28906631892022 @default.
- W2890663189 countsByYear W28906631892023 @default.
- W2890663189 crossrefType "journal-article" @default.
- W2890663189 hasAuthorship W2890663189A5001204975 @default.
- W2890663189 hasAuthorship W2890663189A5001928949 @default.
- W2890663189 hasAuthorship W2890663189A5002934898 @default.
- W2890663189 hasAuthorship W2890663189A5004037726 @default.
- W2890663189 hasAuthorship W2890663189A5030455508 @default.
- W2890663189 hasAuthorship W2890663189A5041853768 @default.
- W2890663189 hasAuthorship W2890663189A5042110139 @default.
- W2890663189 hasAuthorship W2890663189A5043421969 @default.
- W2890663189 hasAuthorship W2890663189A5044171245 @default.
- W2890663189 hasAuthorship W2890663189A5049504224 @default.
- W2890663189 hasAuthorship W2890663189A5055964030 @default.
- W2890663189 hasAuthorship W2890663189A5060572768 @default.
- W2890663189 hasAuthorship W2890663189A5067155382 @default.
- W2890663189 hasAuthorship W2890663189A5071263994 @default.
- W2890663189 hasAuthorship W2890663189A5071722627 @default.
- W2890663189 hasAuthorship W2890663189A5072962574 @default.
- W2890663189 hasAuthorship W2890663189A5078629724 @default.
- W2890663189 hasAuthorship W2890663189A5087836238 @default.
- W2890663189 hasAuthorship W2890663189A5091816731 @default.
- W2890663189 hasConcept C121608353 @default.
- W2890663189 hasConcept C126322002 @default.
- W2890663189 hasConcept C143998085 @default.
- W2890663189 hasConcept C2775949291 @default.
- W2890663189 hasConcept C2776694085 @default.
- W2890663189 hasConcept C2777292972 @default.
- W2890663189 hasConcept C2777701055 @default.
- W2890663189 hasConcept C2777802072 @default.
- W2890663189 hasConcept C2778239845 @default.
- W2890663189 hasConcept C2780030458 @default.
- W2890663189 hasConcept C2781451048 @default.
- W2890663189 hasConcept C71924100 @default.
- W2890663189 hasConceptScore W2890663189C121608353 @default.
- W2890663189 hasConceptScore W2890663189C126322002 @default.
- W2890663189 hasConceptScore W2890663189C143998085 @default.
- W2890663189 hasConceptScore W2890663189C2775949291 @default.
- W2890663189 hasConceptScore W2890663189C2776694085 @default.
- W2890663189 hasConceptScore W2890663189C2777292972 @default.
- W2890663189 hasConceptScore W2890663189C2777701055 @default.
- W2890663189 hasConceptScore W2890663189C2777802072 @default.
- W2890663189 hasConceptScore W2890663189C2778239845 @default.
- W2890663189 hasConceptScore W2890663189C2780030458 @default.
- W2890663189 hasConceptScore W2890663189C2781451048 @default.
- W2890663189 hasConceptScore W2890663189C71924100 @default.
- W2890663189 hasIssue "15_suppl" @default.
- W2890663189 hasLocation W28906631891 @default.
- W2890663189 hasOpenAccess W2890663189 @default.
- W2890663189 hasPrimaryLocation W28906631891 @default.
- W2890663189 hasRelatedWork W2053778437 @default.
- W2890663189 hasRelatedWork W2061440113 @default.
- W2890663189 hasRelatedWork W2080607747 @default.
- W2890663189 hasRelatedWork W2289428780 @default.
- W2890663189 hasRelatedWork W2395106973 @default.
- W2890663189 hasRelatedWork W2771290640 @default.
- W2890663189 hasRelatedWork W3118834521 @default.
- W2890663189 hasRelatedWork W4200445711 @default.
- W2890663189 hasRelatedWork W4235522950 @default.
- W2890663189 hasRelatedWork W4246343941 @default.
- W2890663189 hasVolume "36" @default.
- W2890663189 isParatext "false" @default.
- W2890663189 isRetracted "false" @default.
- W2890663189 magId "2890663189" @default.
- W2890663189 workType "article" @default.